Semaglutide gets cheaper in India
Semaglutide prices fell in India this week, widening access to a leading GLP‑1 therapy and spurring debate about safer, supervised use as prescriptions expand. (medindia.net) Parallel mechanistic research is clarifying semaglutide’s kidney and cardiovascular benefits—new REMODEL coverage and expert interviews could influence prescribing for CKD patients. (hcplive.com)
India’s semaglutide patent expired on March 20, 2026, and Indian manufacturers began launching generics priced as low as ₹1,290 per month (~$14) with pen-device starter packs expected around ₹4,500, a cut of up to about 80% versus branded imports. (bloomberg.com (bloomberg.com); cnbc.com (cnbc.com)) (bloomberg.com) Regulators and industry filings show more than 40–50 branded generic semaglutide products are lining up, with named entrants including Sun Pharma, Dr Reddy’s, Zydus, Glenmark and Natco as they rush to capture the market. (fiercepharma.com (fiercepharma.com); ndtv.com (ndtv.com)) (fiercepharma.com) Dr Reddy’s says its DCGI-approved injectable — Obeda™ in a prefilled disposable pen — will retail at about ₹4,200 per month, a figure cited in regulatory notices and company statements. (pearceip.law (pearceip.law)) (pearceip.law) State regulators have already issued public advisories: Telangana’s Drugs Control Administration on March 24, 2026 warned semaglutide is prescription-only, urged reporting of illegal sales, and told manufacturers not to engage in surrogate advertising as misuse and unsupervised consumption surge. (thehindu.com (thehindu.com); medicaldialogues.in (medicaldialogues.in)) (thehindu.com) The REMODEL mechanistic trial (106 adults with T2D and stage‑2/3 CKD, randomized 2:1 to semaglutide 1 mg weekly vs placebo for 52 weeks) reported reductions in kidney fat, improved glomerular hemodynamics, lower albuminuria and signs of reduced endothelial injury on imaging and biopsy-based analyses. (isn.org (theisn.org); healio.com (healio.com)) (theisn.org) REMODEL coverage and an HCPLive interview with Petter Bjornstad, MD (published March 28, 2026) frame those mechanistic signals as a potential rationale for expanding semaglutide prescribing in CKD populations, adding clinical nuance to pricing- and access-driven uptake. (hcplive.com (join.hcplive.com); asn-online.org (asn-online.org)) (hcplive.com)
